[Toxic and adverse neurological effects of anti-parkinsonian drugs].
Sunohara
N
N
Department of Neurology, National Hakone Hospital.
D000547:Amantadine / Q000009:adverse effects; D000978:Antiparkinson Agents / Q000009:adverse effects*; D001971:Bromocriptine / Q000009:adverse effects; D018680:Cholinergic Antagonists / Q000009:adverse effects; D015259:Dopamine Agents / Q000009:adverse effects*; D004409:Dyskinesia, Drug-Induced; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D009459:Neuroleptic Malignant Syndrome; D011605:Psychoses, Substance-Induced; D019966:Substance-Related Disorders
D000978:Antiparkinson Agents; D018680:Cholinergic Antagonists; D015259:Dopamine Agents; D001971:Bromocriptine; D007980:Levodopa; D000547:Amantadine